Lordan J T, Karanjia N D, Quiney N, Fawcett W J, Worthington T R
The Royal Surrey County Hospital, Guildford, Surrey, UK.
Eur J Surg Oncol. 2009 Mar;35(3):302-6. doi: 10.1016/j.ejso.2008.01.028. Epub 2008 Mar 6.
Colorectal carcinoma is the second most common cause of cancer death in the western world and nearly 50% of patients develop liver metastases. Many cancers are managed via a multidisciplinary team process. This study compares the long term outcome of patients with metastatic colorectal cancer referred via a multidisciplinary team including a liver surgeon (MDT) with those referred directly to a specialist hepatobiliary unit.
This is a prospective study of 331 consecutive referrals made to a specialist hepatobiliary unit over ten years out of which 108 patients were referred via a colorectal MDT which included a liver surgeon and 223 were directly referred via colorectal MDTs without a liver surgeon. Pre-operative assessment and management were standardised and short and long term data were recorded.
Patients referred via the MDT had 1-, 3- and 5-year survival rates of 89.6%, 67.5% and 49.9% respectively and 1-, 3- and 5-year disease-free survival of 65.4%, 31% and 27.2% respectively. Patients referred directly had 1-, 3- and 5-year survival rates of 90.3%, 54.1% and 43.3% respectively and 1-, 3- and 5-year disease-free survival rates of 70.3%, 37.6% and 27.9% respectively. The difference in overall survival was significant (P=0.0001), although the difference in disease-free survival was not (P=0.21).
Assessing, managing and referring patients with metastatic colorectal cancer via a multidisciplinary team including a liver surgeon is associated with improved overall survival.
在西方世界,结直肠癌是癌症死亡的第二大常见原因,近50%的患者会发生肝转移。许多癌症通过多学科团队流程进行管理。本研究比较了通过包括肝脏外科医生在内的多学科团队转诊的转移性结直肠癌患者(多学科团队组)与直接转诊至专科肝胆科的患者的长期结局。
这是一项对10年间连续转诊至专科肝胆科的331例患者的前瞻性研究,其中108例患者通过包括肝脏外科医生的结直肠癌多学科团队转诊,223例患者通过无肝脏外科医生的结直肠癌多学科团队直接转诊。术前评估和管理标准化,并记录短期和长期数据。
通过多学科团队转诊的患者1年、3年和5年生存率分别为89.6%、67.5%和49.9%,1年、3年和5年无病生存率分别为65.4%、31%和27.2%。直接转诊的患者1年、3年和5年生存率分别为90.3%、54.1%和43.3%,1年、3年和5年无病生存率分别为70.3%、37.6%和27.9%。总生存率的差异具有显著性(P = 0.0001),尽管无病生存率的差异不显著(P = 0.21)。
通过包括肝脏外科医生的多学科团队评估、管理和转诊转移性结直肠癌患者可提高总生存率。